graph EGM comparisons
atezolizumab plus bevacizumabtitleatezolizumab alonetitlesunitinibtitleIMmotion-150 (At - PDL1>1%), 2018 NCT01984242 mRCC - L1 - PDL1 positive 54/60IMmotion-151 (PDL1 >1%), 2019 NCT02420821 mRCC - L1 - PDL1 positive 178/184IMmotion-150 (AtB - PDL1>1%), 2018 NCT01984242 mRCC - L1 - PDL1 positive 50/60

Pathology:  mRCC - L1 - PDL1 positive; 

mRCC - L1 - PDL1 positive
IMmotion-150 (At - PDL1>1%), 2018IMmotion-151 (PDL1 >1%), 2019IMmotion-150 (AtB - PDL1>1%), 2018
atezolizumab plus bevacizumab2T1T1
atezolizumab alone1T1
sunitinib0T0T0T0